First in the World! Arbele’s CDH17xCD3 Bispecific Antibody Received Clinical Trial Phase I Ethics Approval in Australia
On March 31, 2022, the clinical trial application of ARB202 received ethics approval in Australia.…
On Childhood Cancer Day, SHEPHERD Therapeutics is joining forces with Oncoheroes Biosciences to bring new treatment options to children and adolescents with cancer. SHEPHERD is a Boston-based biotech company on a mission to change the way rare cancer is treated, including childhood cancers.
“SHEPHERD and Oncoheroes are coming together in hope and in action, leveraging the full extent of our combined technology, experience, and expertise to help save lives,” said David Hysong, CEO of SHEPHERD.
Read more: https://oncoheroes.com/press-releases-content/2021/2/12/shepherd-therapeutics-and-oncoheroes-biosciences-to-partner-for-the-discovery-development-and-commercialization-of-oncology-therapeutics-for-rare-cancers?ss_source=sscampaigns&ss_campaign_id=60269df0bb649d04e8937b30&ss_email_id=602aa8cd0c09d041379337d6&ss_campaign_name=NEWS%21+Oncoheroes+%26+SHEPHERD+Therapeutics+United+Against+Rare+Cancers&ss_campaign_sent_date=2021-02-15T17%3A01%3A48Z